CryoLife Rebuilds Processing Capacity, Eyes Profitability After FDA Reprieve
This article was originally published in The Gray Sheet
Executive Summary
CryoLife credits San Francisco-based Acumen Sciences for guiding it through an FDA Form 483 and a subsequent recall of cardiac, orthopedic and vascular tissue products